BioCryst Pharmaceuticals Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 10/11/2026)
| Balance Sheet | Total Assets | 514,158,000.00 | ROE | -23.17 % |
| Balance Sheet | Total Equity | -119,153,000.00 | ROA | 51.32 % |
| Cashflow | Capital Expenditures | -2,468,000.00 | P/FCF | 5.10 |
| Cashflow | Free Cash Flow | 344,900,992.00 | – | – |
| Cashflow | Operating Cash Flow | 347,369,000.00 | P/CF | 5.07 |
| Income | Earnings per Share (diluted) | 1.21 | Div. Yield | – |
| Income | Net Income | 263,861,000.00 | P/E | 6.65 |
| Income | Shares Outstanding | 218,581,000.00 | P/B | -14.77 |
| Income | Total Revenue | 874,837,000.00 | P/S | 2.01 |
Ratios calculated on: 10/14/2026
Company Description
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza. The Company has two purine nucleoside phosphorylase (PNP) inhibitors that are in development, BCX4208 for the treatment of gout and forodesine for the treatment of hematological malignancies. The Company´s pre-clinical compounds include BCX4161, an oral prophylactic drug for hereditary angioedema, and BCX5191, an adenine nucleoside analog targeting viral ribonucleic acid (RNA) polymerase for the treatment of hepatitis C.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.biocryst.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more